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Abstract
Introduction: Vulvovaginitis is an inflammatory process that affects 
the vulva, vagina and cervix, most of the times of infectious cause. 
Vulvovaginal candidiasis is the second most frequent cause in Brazil, 
in Europe ranks first. Candida spp can be found in the vagina up to 
20% of asymptomatic women.
Objective: Understanding the occurrence of vaginal yeasts and eva-
luating the antifungal action of a red propolis extract.
Method: This is a clinical study in vitro with vaginal secretion samples 
collected from 197 patients treated at the Health Center Frei Damiao 
in Patos-PB, Brazil. The species were identified using a chromogenic 
medium CHROMagar Candida®. At the end, the antifungal activity of 
the red propolis extract in four different concentrations was observed: 
25%, 50%, 75% and 100%, by test disc Agar diffusion. The study was 
approved by the Research Ethics Committee of the Federal University 
of Campina Grande, CAAE 35203614.8.0000.5575.
Results: Of the samples analyzed other species identified by the me-
dium used were the most prevalent corresponding to 59.8%, followed 
by C. albicans, with 21.7%. The antifungal activity was observed in 
81.25% of the tested samples. According to the average and standard 
deviation of the inhibition zone of the four concentrations, the one 
that presented the smallest variation was the concentration at 50%, 
followed by concentration to 75%. 
Conclusions: The results of this research showed that there was 
antifungal action of red propolis extract, since occurred inhibition in 
81.25% of the analyzed samples. However did not show clearance 
regarding this action, since positivity tendency was not growing by 
increasing or decreasing the concentration of propolis extract.
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Introduction
The vulvovaginal candidiasis (VVC) is an infection 
characterized by white, odorless vaginal morbid dis-
charge, associated with vulvar and vaginal lesions, 
itching and burning. It affects more often pregnant 
patients, diabetic and who used antibiotics. Diagno-
sis is based on signs and symptoms and laboratory 
tests [1].
The therapy for this infection is restricted, limi-
ted to the polyene and azole. Nystatin has been 
used for decades; however therapeutic failures were 
observed [2-3]. Of the azole fluconazole is one of 
the most widely used; however, has shown the oc-
currence of strains with decreased sensitivity, and 
other resistant in vivo and in vitro, to certain an-
tifungal agents, side effects and high recurrence 
rates [1,4].
In view of this, the natural products have been 
traditionally used in the treatment of diseases, be-
cause they are sources of many actives, and these 
are the basis for the vast majority of anti-infective 
therapies in current clinical in use [5].
Thus, propolis is a natural product, of a resinous 
aspect, variable chemical composition, collected 
from various plant species by honey bees that add 
salivary secretions; being considered an organothe-
rapic, which means product obtained from glands, 
organs, tissues and animal secretions [6].
Propolis is a complex mixture composed of bal-
samic resin material, collected by honey bees from 
flowers, plant exudates or other parts of the plant 
tissue plus wax, pollen and products of their me-
tabolism, as the enzyme salivary β-glycosidase, res-
ponsible for the hydrolysis of flavonoid glycosides in 
aglucones increasing its pharmacological action [7].
In Brazil, biological properties and different che-
mical compositions are described for samples collec-
ted in different regions of the country. This variation 
can be explained by the Brazilian biodiversity [6]. 
The Brazilian propolis was identified and classified 
into 12 main groups, according to geographic re-
gion of origin and the vegetation from which it was 
extracted the chemical composition [8].
Recently, a new group of Atlantic Forest in the Sta-
tes of Alagoas, Paraiba, Pernambuco, Bahia and Ser-
gipe was ranked as the 13th type of Brazilian propolis, 
called red propolis. It had its botanical origin identi-
fied as Dalbergia ecastophyllum (L) Taub, known po-
pularly as Bugiu-of-Tail, a species of legume with di-
fferent physical and chemical characteristics of other 
samples from 12 groups, and has a potent biological 
action [9-10]. This biological potential of this natural 
product is due to a synergism that occurs between 
its many components [11]. In addition, the Brazilian 
propolis is known for its antifungal activity [12].
Moreover, the interest of researchers from around 
the world has been awakened to use propolis, es-
pecially, its therapeutic properties: antimicrobial, 
anti-inflammatory, immunomodulatory, antioxidant, 
antitumor and antiviral [13].
The ability of propolis to inhibit the growth of 
microorganisms is the pharmacological activity 
more popularly known and scientifically proven [14]. 
Considering that the Brazilian propolis has been the 
subject of intensive research in recent decades, this 
research aimed to identify, in women attending in 
a gynecology clinic of the countryside of Paraiba 
(Brazil), vaginal yeasts and the antifungal activity of 
red propolis extract.
Material and Method
This is a clinical study in vitro with vaginal secre-
tion samples collected from 197 patients treated at 
Health Center Frei Damião, in the municipality of 
Patos-PB (Brazil), in the period from July to Novem-
ber 2014. The patients agreed to participate in the 
research, by clarifying and signing of the Informed 
Consent. In compliance with Resolution 466/12, the 
research was approved by the Research Ethics Com-
mittee of the Federal University of Campina Grande, 
CAAE 35203614.8.0000.5575 protocol.
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Gynecological examination was performed to 
speculate, for the purpose of collecting vaginal dis-
charge using swuab (culture swuab transport system 
- COPAN). Samples of vaginal secretions were obtai-
ned from collections recommended previously [15-
16]. Analyses were performed in the Microbiology 
Laboratory Technological Vocation Center, Federal 
University of Campina Grande, campus of Pombal, 
Paraíba. The material was seeded onto plates con-
taining Sabouraud Agar (Sabouraud Dextrose Agar 
- Difco). The plates were incubated at 37°C for 72 
hours. After this period the reading was performed 
and checked the growth of Candida colonies cha-
racteristics. The identification takes place through 
the study of macroscopic and biochemical aspects 
Chrom Agar Candida® (Probac Brazil), a means of 
chromogen culture that allows identifying presump-
tive action of yeasts, because it contains several en-
zymatic substrates hydrolyzed by the corresponding 
hexoaminidases allow to identify action yeast accor-
ding to the colony pigmentation displayed in a time 
of 24 to 48 hours [17]. The medium used indicates 
green colonies, for C. albicans; Rugose Rose for C. 
krusei; metallic blue, for C. tropicalis; white and 
violet, for other species. The reading of the plates 
and the interpretation of results were carried out 
by observing the morphology and pigmentation of 
the colonies [18].
The red propolis samples were obtained from a 
beekeeper from the coast of Paraíba of Apis mellife-
ra bees arising from the Dalbergi frutescens (Bugiu-
of-Tail), in which the statement was made to 30% 
of ethyl alcohol PA [10]. The antifungal activity of 
the propolis extract was analyzed in four different 
concentrations: 100%, 75%, 50% and 25% (dilu-
tion ethyl alcohol 70%) and was determined by the 
Agar diffusion test, in which samples of Candida 
were grown on Sabouraud agar and incubated at 
37°C/48h. Then, filter paper discs were soaked used 
with 10μL extract at the concentrations and deposi-
ted on the surface of Sabouraud agar containing the 
colonies of Candida sp. The plates were incubated 
at 37°C/48h. After it the measurement was made 
with a caliper, of the halos of inhibition of Candida 
growth. From the results, it was considered active 
product against the species of the microorganisms 
under study which produced halos that above 10 
mm in diameter [19].
Results
Vaginal secretion: species of Candida 
identified
The results of vaginal culture of 197 participants 
showed that 46.2% (n = 91) were positive for some 
species of Candida. Noting that, in a sample, there 
were identified two species and the patient was as-
ymptomatic. The data in Table 1 show the species 
identified in samples whose culture was positive. By 
Table 1. Species of Candida identified in the samples of culture of vaginal secretion (n = 91).
Species of Candida n %
Other species* 55 59.8
C. albicans 20 21.7
C. tropicalis* 15 16.3
C. krusei 2 2.2
Source: Research data. Patos-PB, 2014.
* In a sample there were identified two species (C. tropicalis and Other species)
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those findings, prevailed for other species unidenti-
fied culture medium with 59.8% (n = 55), followed 
by the species C. albicans, with 21.7% (n = 20) and 
of C. tropicalis with 16.3% (n = 15).
It was noticed by the findings that the percentage 
of symptomatic women 85% (n = 17) was higher in 
the kind of C. albicans, compared to 53.52% (n = 
38) of species other than albicans. (Data not shown 
in table).
In table 2, divided the groups of species of 
Candida in C. albicans and non-albicans, there are 
presented according to age and characteristics of 
the menstrual cycle of the women interviewed. It 
appears that the percentage of C. albicans species 
37.5% was higher in younger women, compared to 
the lowest percentage of this kind 4.7% in women 
of higher age, demonstrating statistical dependence 
between variables (p = 0.001) since by increasing 
the age of women it was reduced the percentage 
of species C. albicans and increased of the non-albi-
cans. Moreover, the variables of species of Candida 
and menstrual cycle characteristics did not show 
statistically dependence (p = 0.122), although there 
was a tendency to increase the percentage of C. 
albicans in women with menstrual cycles present. 
(Table 2)
Antifungal action of red propolis extract
Of the 91 vaginal secretion samples with the pre-
sence of Candida, only 48 samples formed fungal 
growth with the number of colonies sufficient to 
conduct the inhibition test with extracts of propolis, 
according to the method used for this purpose.
When testing the antifungal action of red propo-
lis extract on 48 samples referred to, it was noticed 
that in 81.25% (n = 39) the result was positive, for-
ming halo of inhibition higher than 10 mm. Howe-
ver, the positive antifungal action prevailed in 95% 
(n = 19/20) on C. albicans, followed by 87.5% in C. 
tropicalis (n = 7/8) (Table 3).
Facing the different extract concentrations of red 
propolis, added to samples with identification of 
Candida species, it was possible to identify variations 
of 12 to 100 mm in positivity of antifungal action, 
considering that this action is only proven in the 
presence of halo of inhibition greater than 10mm. 
Thus, Table 4 shows that, according to the average 
and standard deviation of the inhibition halo of the 
four concentrations, presented the lowest change 
was the concentration at 50%, followed by con-
centration to 75%.
Table 2.  Distribution of species of Candida according to age and characteristics of the menstrual cycle of 
the interviewed.
Variables
Species of Candida
pC. albicans (n = 20) Non C. albicans (n = 71)
n % n %
Age
(in years)
14 - 38 (n = 48) 18 37.5 30 62.5 <0.001*
39 - 79 (n = 43) 2 4.7 41 95.3
Menstruation**
Present (n = 75) 19 25.3 56 74.7 0.122*
Absent (n = 14) 1 7.1 13 92.9
Source: Research data. Patos-PB, 2014.
p - Chi-square Test (X2) or * Fisher Exact Test; Statistical significance if p < 0.05.
**Excluded two hysterectomized.
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The data shown in Table 4 indicate that the lowest 
and highest number of cases of positive antifungal 
action, respectively, were found at a concentration 
of 100% (n = 17) and 25% (n = 35). This association 
was not observed in the average positive aspects of 
mergers, as the lowest average/standard deviation 
difference was found in the concentration to 50%. 
Thus, considering the greater appearance of inhi-
bition zones, there are indications that the lowest 
concentration of propolis extract has a higher anti-
fungal action.
It is also noticed that although there was total 
inhibition (100mm) in a sample tested at a concen-
tration of 100%, the concentration with the highest 
quantity of positivity in the samples tested was 25% 
(87.2% n = 35/39), with inhibition zones ranging 
from 12 to 80mm; and the positivity of 20, 30, 
40 and 50mm were observed at all concentrations. 
(Table 4)
Discussion
Fungal vulvovaginitis is caused predominantly 
by the genus Candida, being C. albicans the most 
prevalent. But actually there has been an increase 
in species non-albicans, in some populations. The 
greatest concern lies in the fact that these other 
species, in general, tend to be more resistant to 
antifungal agents [20-21].
It is estimated that about 75% of adult women 
have at least one episode of fungal VVC in their life. 
Of these, 40 to 50% experience further outbreaks 
and 5% become applicants. On the other hand, stu-
dies indicate that 20-25% of asymptomatic healthy 
women and have positive cultures of vaginal dis-
charge for yeast and that among the colonized pa-
tients, about 50% present VVC at some point in 
their life [20, 22].
About 80 to 90% of cases of VVC are due to 
species C. albicans and 10 to 20% of the species 
non-albicans (C. tropicalis, C. glabrata, C. krusei, C. 
parapsilosis, C. pseudotropicalis, C. lusitaniae) [23]. 
However, studies show that, in some populations, 
the frequency of isolation of yeasts non-C. albicans 
has increased [20].
Other authors have also observed the predomi-
nance of non-albicans species. In a study with 4.228 
Italian women met in gynecology services found 
a higher prevalence of non-albicans, 57.2% [24]. 
Similar in another study involving 44 women with 
candidiasis history, they found 40.91% of positive 
cultures for Candida spp and of these, identified 
52.63% of non- C.albicans [25].
Table 3.  Distribution of species of Candida identified in the culture of vaginal secretion, according to the 
antifungal action of red propolis extract (n=48).
Species of Candida
Positive
n %
C. albicans (n = 20) 19 95.0
C. tropicalis (n = 08) 7 87.5
Other species (n = 18) 12 66.7
C. krusei (n = 2) 1 50.0
Source: Research data. Patos-PB, 2014.
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Regarding the Candida species found in the sam-
ple investigated (Table 1), it is known that up to 
40% of women may have one or more species, 
as constituent of the vaginal flora without symp-
toms [26]. Other researchers believe that most vul-
vovaginitis is caused by a single species of Candida. 
However two or more species may be involved si-
multaneously [27].
Following the increasing trend of Candida non-
albicans species, this study showed a predominance 
of these, corresponding to 78.3% of the species 
(Table 1). The reasons for this increase in non-albi-
cans species, over the years, are the inappropriate 
use of topical and systemic antifungal once more 
select species resistant to antifungal agents most 
widely used. Studies have linked the emergence of 
C. albicans species not to the use of fluconazole 
[28- 29].
In turn, researchers [30] reported that the erro-
neous, inappropriate or incomplete use of antifun-
gals would enable the elimination of C. albicans 
most sensitive species, selecting the most resistant 
non-albicans. Furthermore, it is reported that various 
antifungal agents such as clotrimazole, ketoconazo-
le, miconazole, nystatin, butoconazole, are not ac-
tive in vitro or in vivo against non-albicans species 
Table 4.  Results of antifungal action of red propolis extract in concentrations to 100%, 75%, 50% and 
25% (n=39).
Results (mm)
Concentrations of propolis extract
100%
(43.6% n = 17)
75%
(53.8% n = 21)
50%
(51.3% n = 20)
25%
(89.7% n = 35)
Average (SD) 40.00±22.492 30.00±13.684 27.7±11.973 30.00±18.991
Minimum-Maximum 20-100 15-60 20-50 12-80
12 mm - - - 2.9% ( = 1)
15mm - 14.3% ( = 3) - 8.6% (= 3)
20 mm 41.2% ( = 7) 28.6% ( = 6) 45.0% (= 9) 20.0% ( = 7)
21mm - - - 2.9% ( = 1)
23mm - - - 2.9% ( = 1)
25mm - - 5.0% ( = 1) 2.9% ( = 1)
28mm - - - 2.9% ( = 1)
30 mm 5.9% (= 1) 19.0% (= 4) 20.0% ( = 4) 14.3% ( = 5)
35mm - - - 2.9% ( = 1)
40 mm 5.9% (= 1) 19.0% ( = 4) 10.0% ( = 2) 14.3% ( = 5)
50 mm 23.5% ( = 4) 14.3% ( = 3) 20.0% ( = 4) 11.4% ( = 4)
60 mm 17.6% ( = 3) 4.8% ( = 1) - 5.7% ( = 2)
80mm - - - 8.6% ( = 3)
100mm 5.9% (= 1) - - -
Source: Research data. Patos-PB, 2014.
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[30-31]. However, other factors can contribute: the 
geographical location, the characteristics of the stu-
died populations and other inherent in the diagnosis 
[20,27]. Since non-albicans species show a significant 
association with absence of symptoms [32].
Several authors associated the presence of symp-
toms with the isolation of C. albicans and other 
species, to the absence of symptoms [32]. A study 
with 223 samples identified Candida spp in 31% of 
symptomatic women and in 8% of asymptomatic 
women; and non-albicans species corresponded to 
33% of asymptomatic group and 13% of sympto-
matic [33].
Regarding the association between the presence 
of Candida and the age of the participants recently 
survey did not observe this relationship, since the 
average age of cultures positive for Candida was 
37 years old, ranging from 14 to 65 years old [34]. 
Other research found that the higher frequency of 
patients with positive cultures was between 14 and 
46, and showed no association between the iden-
tified species of yeast and the age of the patients 
[35].
Regarding the menstrual cycle it was observed 
that when regular, was significantly associated with 
vulvovaginal candidiasis; and explained that it is pos-
sible that estrogen peaks facilitate fungal invasion 
of the vaginal mucosa [36].
The presence of regular menstrual cycles have 
been identified as relevant, since the acidity sub-
sequent to hormone peaks of FSH, LH, estradiol 
and progesterone may contribute to the invasion 
of the vaginal mucosa [33]. Moreover, it is possible 
to relate the high levels of estrogen and a positive 
culture for Candida. It is believed that, due to higher 
estrogen levels, the incidence of symptoms is higher 
in women of reproductive age [35].
About antifungal action of propolis extract, veri-
fied in this study, other researchers also found such 
action on different Candida species in sensitivity fo-
llowing order: C. albicans > C. tropicalis > C. krusei 
> C. guilliermondii [37].
Several studies have demonstrated the action of 
propolis on yeast, especially on C. albicans [12,38]. 
Despite the differences in propolis composition stu-
dies at different times and in different regions de-
monstrated their antifungal activity [39-40].
Comparing the activities of propolis and flucona-
zole against Candida spp isolated from the mouths 
of HIV-positive patients, researchers found that pro-
polis extract was able to inhibit the yeast with a 
minimum inhibitory concentration (MIC) less than 
fluconazole [41]. Propolis also showed antifungal 
activity against dermatophytes C. neoformans and 
onychomycosis and exhibited a synergistic effect 
with macrophages against Paracoccidioides brasi-
liensis.
Some research found that the ethanol extract of 
propolis has fungistatic activity at a concentration of 
0.55 mg/ml [42]. Other studies have demonstrated 
fungicidal activity at concentrations of 3 to 7 mg/
ml, being more susceptible species C. albicans [43].
This difference is due to different strains analyzed 
because researchers gave the antifungal potential 
of propolis in asymptomatic and symptomatic pa-
tients, compared to Nystatin, which obtained posi-
tive results before the vulvovaginal candidiasis [44].
Moreover, it can still be related to the isolation 
site and also the virulence of the agent in question, 
since studies underscore the yeast’s ability to adhere 
to infect and cause disease by its potential virulence 
and pathogenicity, determined by virulence factors 
expressed genetically, when subjected to certain si-
tuations [45].
An in vivo study in Paraná noted that the propolis 
extract has shown activity similar to Nystatin, with 
inhibition profile of the vaginal infection by different 
Candida species [46]. The antifungal and antibac-
terial activities of propolis are attributed mainly to 
pinocembrine flavonona, the galargina flavonol and 
phenylethyl ester of caffeic acid, substances whose 
mechanism of action is probably in inhibiting bac-
terial RNA polymerase [47]. The compounds flavo-
noids, caffeic acid, cinnamic acid and benzoic acid, 
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probably acting on the wall or cell membrane of 
microorganisms, causing structural damage [13].
Conclusion
Despite the antifungal action of propolis extract, 
with inhibition in 81.25% of the samples analyzed, 
it appears that, although the most effective concen-
tration was 25% for all other concentrations also 
observed antifungal action, especially considering 
that there were different strains in different pa-
tients, with varied responses due to particularities.
The positive trend of antifungal action of red 
propolis extract was not increased by increasing or 
decreasing the concentration of propolis extract. 
Therefore, such studies are relevant because of the 
need for new therapeutic alternatives, especially 
low-cost, more efficient and safe for the treatment 
of vulvovaginal candidiasis, considering the few 
treatment options available and the observed resis-
tance of Candida to some usual drugs.
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